Literature DB >> 25936988

Anti-PD-L1 for metastatic triple-negative breast cancer.

Josefine Gibson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25936988     DOI： 10.1016/S1470-2045(15)70208-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  24 in total

Review 1.  Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond.

Authors:  Cristina Migali; Monica Milano; Dario Trapani; Carmen Criscitiello; Angela Esposito; Marzia Locatelli; Ida Minchella; Giuseppe Curigliano
Journal:  Ther Adv Med Oncol       Date:  2016-07-10       Impact factor: 8.168

2.  Ex-vivo assessment of drug response on breast cancer primary tissue with preserved microenvironments.

Authors:  Manuele G Muraro; Simone Muenst; Valentina Mele; Luca Quagliata; Giandomenica Iezzi; Alexandar Tzankov; Walter P Weber; Giulio C Spagnoli; Savas D Soysal
Journal:  Oncoimmunology       Date:  2017-05-30       Impact factor: 8.110

Review 3.  Basis for molecular diagnostics and immunotherapy for esophageal cancer.

Authors:  Joe Abdo; Devendra K Agrawal; Sumeet K Mittal
Journal:  Expert Rev Anticancer Ther       Date:  2016-11-23       Impact factor: 4.512

4.  Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer.

Authors:  Xiangjie Sun; Jie Zhai; Baohua Sun; Edwin Roger Parra; Mei Jiang; Wencai Ma; Jing Wang; Anthony M Kang; Kasthuri Kannan; Renganayaki Pandurengan; Shanyu Zhang; Luisa Maren Solis; Cara L Haymaker; Maria Gabriela Raso; Julia Mendoza Perez; Aysegul A Sahin; Ignacio I Wistuba; Clinton Yam; Jennifer K Litton; Fei Yang
Journal:  Mod Pathol       Date:  2021-11-27       Impact factor: 8.209

5.  Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).

Authors:  X Wang; J Ren; J Zhang; Y Yan; N Jiang; J Yu; L Di; G Song; L Che; J Jia; X Zhou; H Yang; H K Lyerly
Journal:  Clin Transl Oncol       Date:  2015-08-13       Impact factor: 3.405

6.  High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.

Authors:  Tao Qin; Yin-duo Zeng; Ge Qin; Fei Xu; Jia-bin Lu; Wen-feng Fang; Cong Xue; Jian-hua Zhan; Xin-ke Zhang; Qiu-fan Zheng; Rou-jun Peng; Zhong-yu Yuan; Li Zhang; Shu-sen Wang
Journal:  Oncotarget       Date:  2015-10-20

7.  PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient.

Authors:  Zhenhua Li; Pengzhi Dong; Meijing Ren; Yawen Song; Xiaolong Qian; Yiling Yang; Shuai Li; Xinmin Zhang; Fangfang Liu
Journal:  J Cancer       Date:  2016-04-10       Impact factor: 4.207

8.  An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.

Authors:  Giulia Bottai; Carlotta Raschioni; Agnese Losurdo; Luca Di Tommaso; Corrado Tinterri; Rosalba Torrisi; Jorge S Reis-Filho; Massimo Roncalli; Christos Sotiriou; Armando Santoro; Alberto Mantovani; Sherene Loi; Libero Santarpia
Journal:  Breast Cancer Res       Date:  2016-12-03       Impact factor: 6.466

Review 9.  New Immunotherapy Strategies in Breast Cancer.

Authors:  Lin-Yu Yu; Jie Tang; Cong-Min Zhang; Wen-Jing Zeng; Han Yan; Mu-Peng Li; Xiao-Ping Chen
Journal:  Int J Environ Res Public Health       Date:  2017-01-12       Impact factor: 3.390

10.  Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.

Authors:  Yawen Guo; Pan Yu; Zeming Liu; Yusufu Maimaiti; Shan Wang; Xingjie Yin; Chunping Liu; Tao Huang
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.